Jean Hebert is a professor of genetics and neuroscience at the Albert Einstein College of Medicine, and the founder of BE Therapeutics. In this interview, he discusses his strategy of replacing ageing as a pathway to longevity, shifting focus from genetics to brain tissue replacement due to ageing complexities. He emphasizes the potential of gene delivery technology and brain replacement for longevity.
The conversation covers tissue replacement, particularly cortical tissue, and other brain structures like the hypothalamus. Jean addresses surgery challenges, the need for improved techniques, and estimated costs of $3 to $10 billion. We also discuss reversible cryostasis, advancements in cryopreservation, and the ethical implications of brain replacement and destructive uploading, alongside strategies to attract talent and funding to the longevity field.
Podden och tillhörande omslagsbild på den här sidan tillhör Longevity Biotech Fellowship. Innehållet i podden är skapat av Longevity Biotech Fellowship och inte av, eller tillsammans med, Poddtoppen.
